Supriya Lifescience Limited has announced that its manufacturing site in Lote Parshuram has received Good Manufacturing Practice (GMP) certification from the Regulatory Authority of Brazil, ANVISA.

This success in the rigorous GMP inspection underscores Supriya's commitment to the highest quality standards and the excellence of its smart manufacturing practices.

The clearance of this audit marks the successful registration of 8 APIs with CADIFA and will further enable smoother and faster registration of the company's other APIs.

This Successful Inspection paves the way for Supriya Lifescience Ltd. to acquire more customers in the Brazilian Pharmaceutical market.

Brazil's GMP review is known to be challenging, involving stringent requirements. ANVISA actively conducts on-site inspections overseas, meticulously examines not only pharmaceutical quality management on-site but also data integrity, manufacturing facilities, and compliance with GMP in production processes.

Within the industry, passing Brazil's GMP without any issues is publicly recognized as a difficult task, and achieving a flawless inspection is considered a remarkable accomplishment.